

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Nanobiotix Reveals Phase 1 Dose Escalation Data for NBTXR3 in Advanced NSCLC
Details : NBTXR3 is a novel, first-in-class oncology product composed of hafnium oxide nanoparticles. It is being evaluated for unresectable non-small cell lung cancer in combination with durvalumab.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 27, 2025
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide,Cetuximab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Johnson & Johnson
Deal Size : $2,585.0 million
Deal Type : Licensing Agreement
Nanobiotix Amends JNJ-1900 Deal, Extends Cash Visibility to Mid-2026
Details : Company announced the execution of disciplined step in its financial strategy via amending licensing agreement with J&J for NBTXR3 (cetuximab), a first in class radio enhancer in elderly HNSCC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $60 million
March 17, 2025
Lead Product(s) : Hafnium Oxide,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson
Deal Size : $2,585.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
NANOBIOTIX Doses First Patient in Phase 2 Study of NBTXR3 in NSCLC
Details : NBTXR3 is a novel, first-in-class oncology product composed of hafnium oxide nanoparticles. It is being evaluated for unresectable non-small cell lung cancer in combination with durvalumab.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Hafnium Oxide,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
Details : NBTXR3 is a novel, first-in-class oncology product composed of functionalized hafnium oxide nanoparticles, activated by radiotherapy. It is being evaluated for pancreatic cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NANOBIOTIX Receives FDA Protocol Acceptance for NBTXR3 in Stage Three Lung Cancer
Details : NBTXR3 is a novel, first-in-class oncology product composed of functionalized hafnium oxide nanoparticles, activated by radiotherapy. It is being evaluated for recurrent non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2024
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nanobiotix Completes Phase 1 Dose Escalation and Recommended Phase 2 Dose
Details : NBTXR3 is a novel oncology product of hafnium oxide nanoparticles for intratumoral injection, activated by radiotherapy for recurrent non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2024
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $2,730.0 million
Deal Type : Licensing Agreement
Nanobiotix Achieves $20M Milestone for Phase 3 Head and Neck Cancer Study
Details : Nanobiotx received its initial milestone payment, marking progress in the Phase 3 study assessing NBTXR3 (cetuximab), a potential first-in-class radio enhancer for elderly head & neck cancer patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $60.0 million
January 29, 2024
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $2,730.0 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, LianBio will assign to Janssen exclusive rights to develop and commercialize first-in-class radio enhancer NBTXR3 (hafnium oxide) in China, South Korea, Singapore, and Thailand for the treatment of locally advanced head and neck squa...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 26, 2023
Lead Product(s) : Hafnium Oxide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide,Cetuximab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : $34.7 million
Deal Type : Public Offering
NANOBIOTIX Announces Closing of Global Offering
Details : The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 07, 2023
Lead Product(s) : Hafnium Oxide,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : $34.7 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hafnium Oxide,Cetuximab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : $55.0 million
Deal Type : Public Offering
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
Details : The company intends to use the proceeds for the supply of NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, to advance the Company’s Phase 3 in the US and the EU for the treatment of locally advanced head...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 02, 2023
Lead Product(s) : Hafnium Oxide,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : $55.0 million
Deal Type : Public Offering
